FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma
London UK 9 September 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium /... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 10, 2020 Category: Drugs & Pharmacology Source Type: news

Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent(R) Diskus(R)
Company Extends Distribution Term for Generic ADVAIR DISKUS® PHILADELPHIA, Aug. 17, 2020 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreemen... Biopharmaceuticals, Generics, Distribution Lannett Company, Flovent, Diskus, Fluticasone Propionate Powder Inhaler (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 17, 2020 Category: Pharmaceuticals Source Type: news

Fluticasone Propionate Orally Disintegrating Tablets for EoE Fluticasone Propionate Orally Disintegrating Tablets for EoE
A novel fluticasone propionate formulation which dissolves in the mouth and is swallowed without liquids is under investigation for the treatment of eosinophilic oesophagitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Pharmascience Inc. Launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the Maintenance Treatment of Asthma and COPD
MONTREAL, March 18, 2020 -- (Healthcare Sales & Marketing Network) - Pharmascience Inc. is proud to bring to market a new product for the maintenance treatment of asthma and COPD. pms-FLUTICASONE PROPIONATE/SALMETEROL DPI, a generic alternative to ADVAIR ... Biopharmaceuticals, Generics, Drug Delivery, Product Launch Pharmascience, FLUTICASONE, SALMETEROL, ADVAIR DISKUS, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2020 Category: Pharmaceuticals Source Type: news

Airduo Digihaler (Fluticasone Propionate and Salmeterol Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 6, 2020 Category: Drugs & Pharmacology Source Type: news

Dymista (azelastine hydrochloride and fluticasone propionate)
Title: Dymista (azelastine hydrochloride and fluticasone propionate)Category: MedicationsCreated: 4/20/2015 12:00:00 AMLast Editorial Review: 12/2/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - December 2, 2019 Category: Allergy & Immunology Source Type: news

Lannett Enters Into Distribution Agreement For Generic ADVAIR DISKUS(R)
PHILADELPHIA, Oct. 1, 2019 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (F... Biopharmaceuticals, Generics, Distribution Lannett Company, ADVAIR DISKUS, Fluticasone Propionate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 1, 2019 Category: Pharmaceuticals Source Type: news

azelastine hydrochloride and fluticasone propionate (Dymista)
Title: azelastine hydrochloride and fluticasone propionate (Dymista)Category: MedicationsCreated: 4/20/2015 12:00:00 AMLast Editorial Review: 8/5/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - August 5, 2019 Category: Allergy & Immunology Source Type: news

fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)
Title: fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)Category: MedicationsCreated: 6/12/2013 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - July 19, 2019 Category: Respiratory Medicine Source Type: news

FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma
JERUSALEM and PARSIPPANY, N.J., July 15, 2019– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 15, 2019 Category: Drugs & Pharmacology Source Type: news

fluticasone furoate nasal spray (Veramyst)
Title: fluticasone furoate nasal spray (Veramyst)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 7/5/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - July 5, 2019 Category: Allergy & Immunology Source Type: news

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles
Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 23, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

EMA Panel Backs Triple Therapy Inhaler for COPD EMA Panel Backs Triple Therapy Inhaler for COPD
Temybric Ellipta combines fluticasone furoate, umeclidinium, and vilanterol in a single inhaler and is for maintenance treatment of moderate-to-severe COPD.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 27, 2019 Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news

Xhance (Fluticasone Propionate Nasal Spray, for Intranasal Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news

Wixela Inhub (Fluticasone Propionate and Salmeterol Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 21, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus
HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 31, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Generic Version of Advair for Asthma, COPD
THURSDAY, Jan. 31, 2019 -- The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration. The medication can now be used to treat children... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2019 Category: Pharmaceuticals Source Type: news

First Generic Version of Advair Diskus Approved for Asthma, COPD
THURSDAY, Jan. 31, 2019 -- The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration. It can now be used to treat children aged 4 or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 31, 2019 Category: General Medicine Source Type: news

FDA approves first generic Advair Diskus
The U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News)
Source: World Pharma News - January 31, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves First Generic Advair Diskus
January 30, 2019 -- The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news

Arnuity Ellipta (Fluticasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 22, 2019 Category: Drugs & Pharmacology Source Type: news

Drug combo device now also approved for asthma in children
Drug regulators have approved a combination of fluticasone and formoterol in a device that can be used with a spacer for treating asthma in children. (Source: Nursing Times)
Source: Nursing Times - January 14, 2019 Category: Nursing Source Type: news

fluticasone propionate (Cutivate)
Title: fluticasone propionate (Cutivate)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 12/17/2018 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - December 17, 2018 Category: Dermatology Source Type: news

fluticasone propionate oral inhaler (Flovent)
Title: fluticasone propionate oral inhaler (Flovent)Category: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 12/14/2018 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - December 14, 2018 Category: Respiratory Medicine Source Type: news

Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western Europe
This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2018 Category: Pharmaceuticals Source Type: news

Apotex recalls allergy nasal spray due to glass particles
Apotex yesterday issued a voluntary recall of one lot of fluticasone propionate allergy nasal spray devices, noting that they may contain small glass particles. The company first discovered the issue thanks to a customer complaint. The glass particles could block the device’s actuator, according to Apotex, and impact the pump’s functionality. Get the full story at our sister site, Drug Delivery Business News. The post Apotex recalls allergy nasal spray due to glass particles appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Recalls Regulatory/Compliance Respiratory apotex Source Type: news

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles
Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 31, 2018 Category: Food Science Source Type: news

GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled corticosteroid (ICS) medicine for the maintenance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Asthma Inhaler Arnuity Ellipta for Kids as Young as 5 FDA OKs Asthma Inhaler Arnuity Ellipta for Kids as Young as 5
Fluticasone furoate improves lung function in children age 5 to 11 years with asthma when used as a once-daily inhaled maintenance therapy.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - May 22, 2018 Category: Universities & Medical Training Tags: Pulmonary Medicine News Alert Source Type: news

GSK ’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old
GlaxoSmithKline (NYSE:GSK) won FDA approval for the use of its Arnuity Ellipta inhaler as a once-daily therapy for the maintenance treatment of asthma in children as young as five years old. The pharmaceutical company touted its regulatory win, pointing out that the fluticasone furoate treatment is one of the only once-daily asthma therapies cleared in the U.S. for use in this age group. Get the full story at our sister site, Drug Delivery News. The post GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Source Type: news

Bill would limit patient access to cheaper drugs
More than 25 million Americans suffer from asthma. The condition is well-known for restricting a patient ’s airway, making it difficult to breathe and often causing coughing and wheezing. In addition to putting the squeeze on a person’s lungs, asthma is also putting pressure on patients’ wallets, as the cost of inhalers has risen to about $5,000 a year. Doctors and patients were recently elated when a popular asthma medication went generic. Fluticasone/salmeterol is the first-ever generic asthma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 16, 2018 Category: American Health Authors: Dr. John D. Bennett Source Type: news

Trelegy Ellipta (Fluticasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 10, 2018 Category: Drugs & Pharmacology Source Type: news

Dymista (Azelastine Hydrochloride and Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 10, 2018 Category: Drugs & Pharmacology Source Type: news

Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
24 April 2018 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 24, 2018 Category: Drugs & Pharmacology Source Type: news

ArmonAir RespiClick (Fluticasone Propionate Multidose Dry Powder Inhaler for Oral Inhalation) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 16, 2018 Category: Drugs & Pharmacology Source Type: news

What are Indications for Allergen-specific Immunotherapy?
Discussion Allergen-specific immunotherapy (AIT) is a disease modifying treatment for allergic disease. Sometimes referred to as desensitization, the premise is to expose the patient to small but regular amounts of a specific antigen thereby building tolerance within the patient to the allergen. AIT is often underused because of safety concerns and lack of appropriately trained health care providers and facilities to safely carry out AIT treatment. There are 4 main AIT treatments options currently: SCIT – subcutaneous immunotherapy Allergen is injected into the subcutaneous skin “Shots are effective in treati...
Source: PediatricEducation.org - March 5, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 10, 2018 Category: Drugs & Pharmacology Source Type: news

Novartis' Ultibro ® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide® (salmeterol/fluticasone) 50/500 mcg to Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg[1]. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1)[1]. (Source: World Pharma News)
Source: World Pharma News - November 27, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, 'FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News)
Source: World Pharma News - November 23, 2017 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

EU Approves Trelegy Ellipta for COPD EU Approves Trelegy Ellipta for COPD
The European Commission has granted marketing authorization for fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline PLC and Innoviva, Inc) for the treatment of COPD.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

fluticasone (Flonase, Flonase Allergy Relief)
Title: fluticasone (Flonase, Flonase Allergy Relief)Category: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 11/10/2017 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - November 10, 2017 Category: Allergy & Immunology Source Type: news

Flonase vs. Nasacort
Title: Flonase vs. NasacortCategory: MedicationsCreated: 10/30/2017 12:00:00 AMLast Editorial Review: 10/30/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

Trelegy Ellipta (Fluticasone Furoate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Xhance (Fluticasone Propionate Nasal Spray, for Intranasal Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Trelegy Ellipta for COPD FDA Approves Trelegy Ellipta for COPD
The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA approves GSK ’ s 3-in-1 Trelega Ellipta inhaler
The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today. The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler appeared first on Mass...
Source: Mass Device - September 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Optinose Announces FDA Approval of Xhance (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
YARDLEY, Pa.--(BUSINESS WIRE)-- September 18, 2017 -- Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food& Drug Administration (FDA) approved the Company ’s New Drug Application (NDA) for Xhance... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 19, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 19, 2017 Category: Drugs & Pharmacology Source Type: news

CHMP Backs Two New Inhalers Inhalers for COPD CHMP Backs Two New Inhalers Inhalers for COPD
Elebrato Ellipta and Trelegy Ellipta contain the triple combination of fluticasone furoate, umeclidinium, and vilanterol and are for inadequately controlled moderate to severe COPD in adults.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news